A Study of Enfortumab Vedotin Plus Pembrolizumab and/or Chemotherapy for Patients With Urothelial Bladder Cancer (EV-103)
Carcinoma, Transitional CellUrinary Bladder NeoplasmsUrologic NeoplasmsRenal Pelvis NeoplasmsUrothelial CancerUreteral NeoplasmsUrethral NeoplasmsASG-22MEASG-22CEAntibody-drug conjugateAntineoplastic agentsCPIEnfortumab vedotinLocally advanced urothelial cancerCisplatinDrug therapyCarboplatinMetastatic urothelial cancerNectin-4GemcitabineCheckpoint InhibitorsPembrolizumabNeoplasmsPelvic NeoplasmsDose Escalation: Enfortumab Vedotin + Pembrolizumab
Lead Scientist at UCSF
- Terence Friedlander
I am a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. My research is focused on understanding the basic biology these malignancies and in developing novel therapeutic ways to treat disease.
- accepting new patients
- Start Date
- Completion Date
- Astellas Pharma Global Development, Inc.
- Phase 1
- Study Type
- Last Updated